|
Assay Guidance Workshop For High Throughput Screening And Lead Discovery
|
Meeting/ Workshop
|
FDA
|
NCATS, NCI, NIAAA, NIDDK
|
More than 40 participants attended the “Assay Guidance Workshop for High-Throughput Screening and Lead Discovery” on August 7, 2017, in Potomac, Maryland. Supported by National Center for Advancing Translational Sciences (NCATS), the workshop was designed to provide participants with a broad and practical perspective on how to develop and implement robust assays for early-stage drug discovery projects. Participants included researchers from four National Institutes of Health (NIH) centers, Food and Drug Administration (FDA), industry, and academia. Workshop leaders with more than 20 years of drug discovery experience covered a broad range of critical concepts underlying robust assay development and screening strategies. There were also open discussions for participants to share experiences and seek practical advice about individual research interests.
|
|
Assisted Outpatient Treatment
|
Research Initiative
|
HRSA, SAMHSA
|
NIMH
|
This collaboration supports the development and implementation of a rigorous and objective cross-site impact evaluation of an Assisted Outpatient Treatment (AOT) Grant Program for Individuals with Serious Mental Illness. The Department of Health and Human Services, Assistant Secretary for Planning and Evaluation (ASPE) has primary responsibility for the solicitation, management, and implementation of the evaluation contract in consultation with the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute of Mental Health (NIMH). The Center for Behavioral Health Statistics and Quality (CBHSQ), an entity within SAMHSA that serves as a focal point for data collection, analysis, and the dissemination of critical public health data, will provide consultation on the cross-site evaluation of the AOT grant program. ASPE, in consultation with the NIMH, brings expertise in evaluation design and implementation that benefits SAMHSA in its priority of having a rigorous multi-site evaluation. The initial Phase I Implementation Evaluation was completed in FY2017. Results of the Implementation Evaluation are being used to inform the design and data collection plan for the Phase II Outcome Evaluation, which is scheduled to begin in FY 2019.
|
|
Autoimmune Diseases Coordinating Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NIAID, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR
|
The purpose of the Autoimmune Diseases Coordinating Committee (ADCC) is to provide a forum for the coordination of research efforts in autoimmunity and autoimmune diseases among various stakeholders including the National Institutes of Health (NIH), other federal agencies such as the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), and private organizations with an interest in autoimmune diseases. The ADCC meets twice yearly to discuss a broad range of basic, preclinical, and clinical endeavors.
|
|
Bacteriophage Interest Group (Monthly Meeting)
|
Meeting/ Workshop
|
BARDA, FDA
|
NIAID
|
The purpose of this monthly meeting is to allowthe National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority(BARDA) and the Food and Drug Administration (FDA) to hear seminars on bacteriophage therapy and discuss progress in this area.
|
|
Bacteriophage Therapy: Intraagency meeting
|
Meeting/ Workshop
|
FDA
|
NIAID
|
The purpose of this meeting is to exchange information regarding phage therapy with other United States Government (USG) stakeholders. The meeting is planned for summer 2021.
|
|
Best Pharmaceuticals for Children Act (BPCA) Data Monitoring Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NCI, NHLBI
|
This group provides safety oversight for all studies conducted under BPCA.
|
|
Biodefense Coordination Team (BCT)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP
|
Coordinates implementation of the U.S. National Biodefense Strategy and Presidential Memorandum on the Support for Biodefense towards an integrated, comprehensive approach to manage biodefense activities in support of the broader biodefense enterprise.
|
|
Bioeconomy Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
OD/OSP
|
Discusses and coordinates policy options related to promoting and protecting the bioeconomy.
|
|
Biological Select Agents and Toxins Interagency Policy Committee (BSAT PPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Discusses appropriate oversight of Select Agents and Toxins.
|
|
Biological Select Agents and Toxins sub-Interagency Policy Committee (BSAT Sub-PPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Discusses the appropriate oversight of Select Agents and Toxins; Subcommittee of the Biological Select Agents and Toxins Policy Coordination Committee (BSAT PPC).
|